慢性肝病患者肌肉减少症干预研究进展*

doi:10.3969/j.issn.1672-5069.2025.06.040

Abstract

Abstract: Sarcopenia is a systemic entity in which muscle mass and strength progressively decline. Sarcopenia is associated with poor outcomes and prognosis in patients with chronic liver disease, particularly in those at the end-stage. On the basis of traditional nutritional supplementation and exercise intervention, the existing intervention are extending more to target therapy for signaling pathways. In this review, we summarized the progress of intervention for sarcopenia in patients with chronic liver disease, in order to provide more references for the clinical management of sarcopenia.

Key words: Chronic liver disease, Sarcopenia, Intervention

Zhang Siqi, Kong Ming, Duan Zhongping. Intervention for sarcopenia in patients with chronic liver diseases[J]. Journal of Practical Hepatology, 2025, 28(6): 957-960.

References

[1] Cruz-jentoft AJ, Sayer AA. Sarcopenia. Lancet, 2019, 393(10191): 2636-2646.
[2] Mazeaud S, Zupo R, Couret A, et al. Prevalence of sarcopenia in liver cirrhosis: A systematic review and meta-analysis. Clin Transl Gastroenterol, 2023, 14(7): e00584.
[3] Montano-loza AJ. Clinical relevance of sarcopenia in patients with cirrhosis. World J Gastroenterol, 2014, 20(25): 8061-8071.
[4] Duong N, Sadowski B, Rangnekar AS.The impact of frailty, sarcopenia, and malnutrition on liver transplant outcomes.Clin Liver Dis (Hoboken),2021, 17(4): 271-276.
[5] Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr, 2019, 38(2): 485-521.
[6] Tsien CD, Mccullough A J, Dasarathy S.Late evening snack: exploiting a period of anabolic opportunity in cirrhosis.J Gastroenterol Hepatol,2012, 27(3): 430-441.
[7] Guo YJ, Tian ZB, Jiang N, et al. Effects of late evening snack on cirrhotic patients: A systematic review and meta-analysis. Gastroenterol Res Pract, 2018, 2018: 9189062.
[8] Bear DE, Langan A, Dimidi E, et al. β-Hydroxy-β-methylbutyrate and its impact on skeletal muscle mass and physical function in clinical practice: A systematic review and meta-analysis.Am J Clin Nutr,2019, 109(4): 1119-1132.
[9] Bischoff SC, Ockenga J, Eshraghian A, et al. Practical guideline on obesity care in patients with gastrointestinal and liver diseases-Joint ESPEN/UEG guideline. Clin Nutr, 2023, 42(6): 987-1024.
[10] Ceglia L.Vitamin D and its role in skeletal muscle. Curr Opin Clin Nutr Metab Care, 2009, 12(6): 628-633.
[11] Okubo T, Atsukawa M, Tsubota A, et al. Effect of vitamin D supplementation on skeletal muscle volume and strength in patients with decompensated liver cirrhosis undergoing branched chain amino acids supplementation:A prospective, randomized, controlled pilot trial. Nutrients, 2021, 13(6): 1874.
[12] Llibre-nieto G, Lira A, Vergara M, et al. Micronutrient deficiencies in patients with decompensated liver cirrhosis. Nutrients, 2021, 13(4): 1249.
[13] Yang W,Wang X,Yu Z,et al.Low levels of serum zinc associate with malnutrition risk assessed by the royal free hospital-nutritional prioritizing tool in cirrhosis. Biol Trace Elem Res, 2022, 200(10): 4289-4296.
[14] Nishikawa H,Enomoto H,Yoh K,et al.Serum zinc concentration and sarcopenia:A close linkage in chronic liver diseases.J Clin Med,2019,8(3): 336.
[15] Aslan A,Beyaz S,Gok O,et al.The effect of ellagic acid on caspase-3/bcl-2/nrf-2/nf-kb/tnf-α /cox-2 gene expression product apoptosis pathway: A new approach for muscle damage therapy. Mol Biol Rep, 2020, 47(4): 2573-2582.
[16] Nakae Y, Hirasaka K, Goto J, et al. Subcutaneous injection, from birth, of epigallocatechin-3-gallate, a component of green tea, limits the onset of muscular dystrophy in mdx mice:A quantitative histological, immunohistochemical and electrophysiological study.Histochem Cell Biol, 2008, 129(4): 489-501.
[17] López-hortas L,Pérez-larrán P,González-muñoz M J,et al.Recent developments on the extraction and application of ursolic acid. A review. Food Res Int, 2018, 103: 130-149.
[18] Kunkel SD, Elmore CJ, Bongers KS, et al. Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease. PLoS One, 2012, 7(6): e39332.
[19] Casciola R, Leoni l, Cuffari B, et al. Creatine supplementation to improve sarcopenia in chronic liver disease: Facts and perspectives. Nutrients, 2023, 15(4): 863.
[20] Chilibeck PD,Kaviani M,Candow DG,et al. Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis. Open Access J Sports Med, 2017, 8: 213-226.
[21] Byeon HR, Jang SY, Lee Y, et al. New strains of akkermansia muciniphila and faecalibacterium prausnitzii are effective for improving the muscle strength of mice with immobilization-induced muscular atrophy. J Med Food, 2022, 25(6): 565-575.
[22] Prokopidis K, Giannos P, Kirwan R, et al.Impact of probiotics on muscle mass, muscle strength and lean mass: A systematic review and meta-analysis of randomized controlled trials.J Cachexia Sarcopenia Muscle,2023,14(1): 30-44.
[23] Sano A, Inoue J, Kakazu E, et al. Association of omega-3 polyunsaturated ftty acids with sarcopenia in liver cirrhosis patients with hepatocellular carcinoma. J Clin Transl Hepatol, 2024, 12(7): 613-624.
[24] Bird JK,Troesch B,Warnke I,et al.The effect of long chain omega-3 polyunsaturated fatty acids on muscle mass and function in sarcopenia: A scoping systematic review and meta-analysis.Clin Nutr ESPEN,2021,46: 73-86.
[25] Aamann L, Dam G, Borre M, et al. Resistance training increases muscle strength and muscle size in patients with liver cirrhosis. Clin Gastroenterol Hepatol, 2020, 18(5): 1179-1187,e6.
[26] Zenith L, Meena N, Ramadi A, et al. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol, 2014, 12(11): 1920-1926.e1922.
[27] Williams FR, Berzigotti A, Lord JM, et al. Impact of exercise on physical frailty in patients with chronic liver disease. Aliment Pharmacol Ther, 2019, 50(9): 988-1000.
[28] Carey EJ, Lai JC, Sonnenday C,et al. A north american expert opinion statement on sarcopenia in liver transplantation. Hepatology, 2019,70(5): 1816-1829.
[29] Kumar A, Davuluri G, Silva RNE, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology, 2017, 65(6): 2045-2058.
[30] Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Ther, 2012, 92(3): 321-331.
[31] Butterworth RF. L-ornithine l-aspartate for the treatment of sarcopenia in chronic liver disease: The taming of a vicious cycle. Can J Gastroenterol Hepatol, 2019, 2019: 8182195.
[32] Chrysavgis L, Adamantou M,Angelousi A,et al.The association of testosterone with sarcopenia and frailty in chronic liver disease. Eur J Clin Invest, 2024, 54(2): e14108.
[33] Sinclair M, Grossmann M, Gow PJ, et al. Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol, 2015, 30(2): 244-251.
[34] Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. J Hepatol, 2016, 65(5): 906-913.
[35] Perrini S, Laviola L, Carreira MC, et al. The gh/igf1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol, 2010, 205(3): 201-210.
[36] Wallace JD, Abbott-johnson WJ, Crawford DH, et al. GH treatment in adults with chronic liver disease: A randomized, double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab, 2002, 87(6): 2751-2759.
[37] Donaghy A, Ross R, Wicks C, et al. Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety. Gastroenterology, 1997, 113(5): 1617-1622.
[38] Rudman D, Sewell CW, Ansley JD. Deficiency of carnitine in cachectic cirrhotic patients. J Clin Invest, 1977, 60(3): 716-723.
[39] Ebadi M, Bhanji RA, Mazurak VC, et al. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol, 2019, 54(10): 845-859.
[40] Hiramatsu A, Aikata H, Uchikawa S, et al. Levocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis. Hepatol Commun, 2019, 3(3): 348-355.
[41] Sartiani L, Spinelli V, Laurino A, et al. Pharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers? Clin Cases Miner Bone Metab, 2015, 12(2): 135-138.
[42] Lin YL, Chen SY, Lai YH, et al. Angiotensin II receptor blockade is associated with preserved muscle strength in chronic hemodialysis patients. BMC Nephrol, 2019, 20(1): 54.
[43] Lee SJ, Lehar A, Meir JU, et al. Targeting myostatin/activin a protects against skeletal muscle and bone loss during spaceflight. Proc Natl Acad Sci U S A, 2020, 117(38): 23942-23951.
[44] Becker C, Lord SR, Studenski SA, et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol, 2015, 3(12): 948-957.
[45] Rooks D, Praestgaard J, Hariry S, et al. Treatment of sarcopenia with bimagrumab: Results from a phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc, 2017, 65(9): 1988-1995.
[46] Sakuma K,Hamada K,Yamaguchi A,et al.Current nutritional and pharmacological approaches for attenuating sarcopenia.Cells,2023,12(19): 2422.
[47] Bouchi R, Fukuda T, Takeuchi T, et al. Insulin treatment attenuates decline of muscle mass in Japanese patients with type 2 diabetes. Calcif Tissue Int, 2017, 101(1): 1-8.
[48] Ferrari U, Then C, Rottenkolber M, et al. Longitudinal association of type 2 diabetes and insulin therapy with muscle parameters in the kora-age study. Acta Diabetol, 2020, 57(9): 1057-1063.
[49] Jin H, Xie W, Hu P, et al. The role of melatonin in sarcopenia: Advances and application prospects. Exp Gerontol, 2021, 149: 111319.
[50] Amstrup AK, Sikjaer T, Pedersen SB, et al. Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women: A randomized placebo-controlled trial. Clin Endocrinol (Oxf), 2016, 84(3): 342-347.
[51] Lo JH,U KP, Yiu T, et al. Sarcopenia: Current treatments and new regenerative therapeutic approaches. J Orthop Translat, 2020, 23: 38-52.
[52] Pourmohammadi-bejarpasi Z, Roushandeh AM, Saberi A, et al. Mesenchymal stem cells-derived mitochondria transplantation mitigates I/R-induced injury, abolishes I/R-induced apoptosis, and restores motor function in acute ischemia stroke rat model. Brain Res Bull, 2020, 165: 70-80.
[53] Mahindran E, Law JX, Ng MH, et al. Mesenchymal stem cell transplantation for the treatment of age-related musculoskeletal frailty. Int J Mol Sci, 2021, 22(19): 10542.
[54] Chen H, Xu C, Zhang F, et al. The gut microbiota attenuates muscle wasting by regulating energy metabolism in chemotherapy-induced malnutrition rats.Cancer Chemother Pharmacol, 2020, 85(6): 1049-1062.

Intervention for sarcopenia in patients with chronic liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wen Wen, Bai Jie, Li Yongguo. Impact of sarcopenic obesity on prognosis of patients with chronic liver diseases [J]. Journal of Practical Hepatology, 2025, 28(4): 481-484.
[2]	Yao Yu, Xu Chunyang, Ren Jiangwu. Prevalence and risk factors of overt hepatic encephalopathy in hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(3): 406-409.
[3]	Zhu Tingting, Chen Yiyun, Xie Fanci, et al. Non-invasive assessment of liver fibrosis reverse in patients with chronic liver diseases [J]. Journal of Practical Hepatology, 2025, 28(2): 169-172.
[4]	Huang Jiawei, Ji Yali, Zhou Ling, et al. SAF score and fatty liver inhibition of progression algorithm in evaluation of liver fibrosis in patients with metabolic associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(1): 48-51.
[5]	Wei Wei, Chu Limin, Wang Chao, et al. Prevalence of nutrition and sarcopenia in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(6): 895-898.
[6]	Zhang Zhiqiang, Fang Jian, Li Dongliang. Strategy and challenges of interventional treatment in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2024, 27(5): 650-653.
[7]	Feng Qian, Wang Rui, Chen Zhong. Acoustic performance of a newly knitted catheter with an improved ultrasonography visibility [J]. Journal of Practical Hepatology, 2024, 27(4): 511-514.
[8]	Zhao Yuwen, Zhu Chuanlong. Management of malnutrition and sarcopenia in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(3): 324-328.
[9]	Wang Wenchuan, Liang Kuopeng, He Ruiling, et al. Prevalence of non-alcoholic fatty liver diseases in patients with type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2024, 27(1): 40-43.
[10]	Lin Ning, Kong Ming, Duan Zhongping. Nutritional intervention for patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2024, 27(1): 151-154.
[11]	Qiu Wanchun, Mao Xiaorong, Deng Lefeng, et al. Sarcopenia in hospitalized patients with liver cirrhosis and its impact on the occurrence of spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2023, 26(5): 674-677.
[12]	Cui Po, Dong Shiming, Nan Yuemin. Prognosis of COVID-19 patients with underlying chronic liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 905-908.
[13]	Lin Ning, Kong Ming, Duan Zhongping. Pathogenesis of sarcopenia in liver diseases [J]. Journal of Practical Hepatology, 2022, 25(2): 301-304.
[14]	Li Weizhi, Li Peijie, Ma Fuquan, et al. Rivaroxaban as an oral anticoagulant in patients with Budd-Chiari syndrome after percutaneous endovascular intervention [J]. Journal of Practical Hepatology, 2021, 24(5): 621-624.
[15]	Bi Zaihong, Hanbai Yila, Wang Bingyuan. Simvastatin: a newface for treatment of patients with chronic liver disease [J]. Journal of Practical Hepatology, 2021, 24(4): 603-606.